Filters








8,417 Hits in 3.7 sec

Hypokalemia After Rituximab Administration in Steroid-Dependent Nephrotic Syndrome: A Case Report

Francesco Guzzi, Mattia Giovannini, Carmela Errichiello, Giulia Liccioli, Francesca Mori, Rosa Maria Roperto, Paola Romagnani
2020 Frontiers in Pharmacology  
Such adverse drug reactions, when mild and self-limiting, can easily be overlooked if not expected or investigated.  ...  The monoclonal antibody rituximab is a commonly used steroid sparing agent for steroid-dependent idiopathic nephrotic syndrome of childhood.  ...  Given the rising use of monoclonal antibodies to treat several clinical conditions, a parallel increase in hypersensitivity reactions to these drugs have been recorded in the literature, including rituximab  ... 
doi:10.3389/fphar.2020.00915 pmid:32625098 pmcid:PMC7311762 fatcat:obfwn2qgajam7l3zthzbvujziu

Ontologies in Medicinal Chemistry: Current Status and Future Challenges

Asuncion Gomez-Perez, Marcos Martinez-Romero, Alejandro Rodriguez-Gonzalez, Guillermo Vazquez, Jose M. Vazquez-Naya
2013 Current Topics in Medicinal Chemistry  
Beyond glossaries or thesauri, ontologies facilitate communication between experts and allow the application of computational techniques to extract useful information from available data.  ...  Reaction Terms Adverse drug reactions 1995 1,641 DDI [90] Drug Discovery Investigations Drug discovery research 0.9 645 EXPO and LABORS [92, 93] EXPO and LABORS Scientific experiments  ...  Acronym Name Main scope Version Terms AERO [106] Adverse Event Reporting Ontology Adverse event reports 12/18/2012 388 ARM [102] Adverse Reactions and Mechanisms Adverse drug reactions  ... 
doi:10.2174/1568026611313050003 pmid:23548021 fatcat:6hyje3smivfldn2svxvnhtsw6i

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

Ajai Chari, Sagar Lonial, Tomer M Mark, Amrita Y Krishnan, Keith E Stockerl-Goldstein, Saad Z Usmani, Anil Londhe, Delores Etheredge, Sarah Fleming, Baolian Liu, Jon Ukropec, Thomas S Lin (+2 others)
2018 Cancer  
Patients received daratumumab 16 mg/kg weekly for 8 weeks, every other week for 16 weeks, and monthly until they developed disease progression, unacceptable toxicity, or 60 days after the drug gained US  ...  Treatment-emergent grade ≥3 adverse events (AEs), serious AEs, and AEs of special interest were collected.  ...  TABLE 3 . 3 Most Frequently Reported Grade 3 or 4 Adverse Events: Daratumumab, N = 348 a Adverse Event No. of Patients (%) Grade 3 or 4 adverse event 175 (50) Drug-related 85 (24) Thrombocytopenia  ... 
doi:10.1002/cncr.31706 pmid:30395359 pmcid:PMC6587745 fatcat:heopjvcz4fbk7chyy3bmsk7mra

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

Emanuel Raschi, Milo Gatti, Francesco Gelsomino, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti
2020 Targeted oncology  
As of February 2020, 30 real-world postmarketing studies have characterized multiple irAEs through international spontaneous reporting systems, namely WHO Vigibase and the US FDA Adverse Event Reporting  ...  This review aims to summarize and critically appraise the current landscape of pharmacovigilance studies, thus deriving take-home messages for oncologists.  ...  Frequent use of multiple therapeutic regimens makes it difficult to disentangle the adverse effects of individual drugs versus drug-drug interactions versus 'innocent bystander' effects [21, 22] .  ... 
doi:10.1007/s11523-020-00738-6 pmid:32725437 fatcat:u2qnhx7o4fe7rldh57ebipcpki

Emerging Therapies in Hereditary Angioedema

Meng Chen, Marc A. Riedl
2017 Immunology and allergy clinics of North America  
The burden of treatment must also be addressed with regard to medication administration difficulties, treatment complications, and adverse side effects.  ...  Multiple new therapies with novel mechanisms of action are currently being investigated and may offer potential solutions to these challenges faced by patients and physicians.  ...  Overall, the drug was well tolerated with no drug-related serious adverse events reported.  ... 
doi:10.1016/j.iac.2017.03.003 pmid:28687111 pmcid:PMC5585075 fatcat:okeaot6rzjbojbzqbr4p6qgvju

T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab

Sean Hammond, Anna Olsson-Brown, Joshua Gardner, Paul Thomson, Serat-E Ali, Carol Jolly, Dan Carr, Lorenzo Ressel, Munir Pirmohamed, Dean Naisbitt
2021 Journal for ImmunoTherapy of Cancer  
Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI.  ...  Our findings highlight the importance of considering all concomitant medications in patients on ICIs who develop immune-mediated adverse reactions.  ...  Contributors SH and AO-B conceptualized the study with their PhD supervisors MP and DJN. AO-B, SH, JG, PT, CJ and LR conducted laboratory experiments.  ... 
doi:10.1136/jitc-2021-002521 pmid:34049931 pmcid:PMC8166637 fatcat:y6ququikobhxjfwxmf33q5fg3e

TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer

Zaoqu Liu, Libo Wang, Chunguang Guo, Long Liu, Dechao Jiao, Zhenqiang Sun, Kunpeng Wu, Yanan Zhao, Xinwei Han
2021 Journal of Cellular and Molecular Medicine  
Using two-independent cohorts, we found the common frequently mutated genes TTN and OBSCN had the significant correlation with higher tumour mutation burden (TMB) and favourable overall survival.  ...  Libo Wang: Conceptualization (supporting); Formal analysis (supporting); Investigation (equal); Software (equal); Supervision (equalDechao Jiao: Conceptualization (equal); Funding acquisition (lead); Investigation  ...  AUTH O R CO NTR I B UTI O N S Zaoqu Liu: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Investigation (lead); Methodology (lead); Project administration (lead); Resources (lead  ... 
doi:10.1111/jcmm.16393 pmid:33624434 fatcat:pp4o3ja2crapxfbk7sg546zk7e

Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition

Yitian Zhou, Volker M. Lauschke
2019 Computational and Structural Biotechnology Journal  
To visualize the gene-drug interaction landscape, we use multidimensional scaling to collapse this similarity matrix into a two-dimensional network.  ...  Specifically, we analyzed the landscape of drug metabolizing enzymes and transporters for 100 top selling drugs as well as all compounds with pharmacogenetic germline labels or dosing guidelines.  ...  Furthermore, epidemiological data from the US shows that adverse drug reactions (ADRs) cause 8.25% and 19.2% increase of hospital stay length and death rate, respectively, and severe ADRs are estimated  ... 
doi:10.1016/j.csbj.2019.11.010 pmid:31890144 pmcid:PMC6921140 fatcat:6ssp44x57jbivgkqow73k5vhzy

Newer therapeutics for hepatitis C

Bhawna Poonia, Shyam Kottilil
2016 Annals of Translational Medicine  
Until recently, treatment for hepatitis C included use of pegylated interferon-α (IFN-α) and ribavirin, which resulted in modest cure rates, despite having significant dose limiting adverse reactions (  ...  Hence, a similar trial should use CCZ in addition to approved DAA regimens to reduce duration of HCV therapy. If proven this approach will change the landscape of HCV therapy world-wide.  ...  Until recently, treatment for hepatitis C included use of pegylated interferon-α (IFN-α) and ribavirin, which resulted in modest cure rates, despite having significant dose limiting adverse reactions  ... 
doi:10.3978/j.issn.2305-5839.2015.10.06 pmid:26889484 pmcid:PMC4731604 fatcat:pndboot63jaf7hktqdlcgvl4qm

Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets

Mateusz Maciejewski, Eugen Lounkine, Steven Whitebread, Pierre Farmer, William DuMouchel, Brian K Shoichet, Laszlo Urban
2017 eLife  
The Food and Drug Administration Adverse Event Reporting System (FAERS) remains the primary source for post-marketing pharmacovigilance.  ...  To address these problems, we mapped drugs to their ingredients and used natural language processing to classify and correlate drug events.  ...  The work of BKS was supported by US National Institutes of Health Grant R01 GM71896 and by R35 GM122481. We thank Dr Duncan Armstrong for his comments and advice on the manuscript.  ... 
doi:10.7554/elife.25818 pmid:28786378 pmcid:PMC5548487 fatcat:bwncooqaerbalku7uybrcugv5m

Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review

Fioravante Capone, Angela Albanese, Giorgia Quadri, Vincenzo Di Lazzaro, Emma Falato, Antonio Cortese, Laura De Giglio, Elisabetta Ferraro
2022 Frontiers in Neurology  
The use of most DMTs is unlicensed during breastfeeding mainly due to the limited data available on the excretion in human milk and on the effects on infants' exposure.  ...  Pregnancy-related issues in women with multiple sclerosis (MS) have been receiving increasing attention, with particular interest for the use of disease-modifying therapies (DMTs) before conception, during  ...  and GQ: conceptualization and reviewing. VD and EFe: conceptualization, supervision, and reviewing. EFa, AC, and LD: methodology and reviewing.  ... 
doi:10.3389/fneur.2022.851413 pmid:35493841 pmcid:PMC9051389 fatcat:dzmwnqyn2ng3vfwo4ccfuzw7s4

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?

Mattia Giovannini, Francesca Mori, Simona Barni, Maurizio de Martino, Elio Novembre
2019 Italian Journal of Pediatrics  
Moreover, research on biological drugs for the treatment of severe asthma is expanding rapidly, with some molecules currently used in adult patients that could be registered also for pediatric use and  ...  However, mepolizumab will likely be accessible soon globally for clinical use.  ...  Even if the vast majority of adverse reactions are represented by mild reactions manageable with a pharmacological treatment of the specific signs and symptoms, severe reactions such as a systemic one  ... 
doi:10.1186/s13052-019-0737-4 pmid:31779657 pmcid:PMC6883618 fatcat:5xw3gfss6jggle65oopr26gnxm

Multimorbidity and Quaternary Prevention (P4)

Dee Mangin, Iona Heath
2015 Revista Brasileira de Medicina de Família e Comunidade  
This approach has led to the current 'epidemic' in morbidity and mortality from adverse drug reactions that now outstrip the target diseases as a cause of death.  ...  The siloed approach to treatment decision making has led inevitably to polypharmacy, and the current 'epidemic' in morbidity and mortality from adverse drug reactions that now outstrips the target diseases  ...  With multimorbidity in particular, this increases vulnerability to excessive investigation and treatment offering no overall benefits, and adding morbidity due to drug interactions and adverse effects.  ... 
doi:10.5712/rbmfc10(35)1069 fatcat:323yrf5zhbg6dmxoqsxtugrjxa

Cell sensitivity, non-linearity and inverse effects

Paolo Bellavite, Andrea Signorini, Marta Marzotto, Elisabetta Moratti, Clara Bonafini, Debora Olioso
2015 Homeopathy  
Here we review hypotheses about homeopathic drug action at cellular and molecular levels, and present a new conceptual model of the principle of similarity based on allosteric drug action.  ...  Low doses or high dilutions of a drug interact only with the enhanced sensitivities of regulatory systems, functioning as minute harmful stimuli to trigger specific compensatory healing reactions.  ...  This is also connected with the use of very small doses of drugs in homeopathy.  ... 
doi:10.1016/j.homp.2015.02.002 pmid:25869978 fatcat:kbvpe2mhabeylg2nejepe35nj4

Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile

Debasish Basak, Scott Arrighi, Yasenya Darwiche, Subrata Deb
2021 Life  
The differences in drug disposition and interaction with human basal pathways contribute to this paradigm shift in adverse effect profile.  ...  In this review, we summarized the general mechanisms and adverse effects of small and large molecule anticancer drugs that would further our understanding on the toxicity patterns of chemotherapeutic regimens  ...  Author Contributions: Conceptualization, S.D.; methodology, S.D., D.B.; software, S.D.; investigation, S.A., Y.D., D.B.; resources, S.D., D.B.; data curation, D.B., S.A., Y.D.; writing-original draft preparation  ... 
doi:10.3390/life12010048 pmid:35054441 pmcid:PMC8777973 fatcat:jgh2z3fxdndvnehrld5vjmlnpi
« Previous Showing results 1 — 15 out of 8,417 results